Selective immunomodulatory activity of SK&F 106615, a macrophage-targeting antiarthritic compound, on antibody and cellular responses in rats and mice

Immunopharmacology

Volumn 37, Issue 1, 1997, Pages 53-61

  Badger, Alison M ^a   Newman Tarr, Tonie M ^a   Satterfield, Jennifer L ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTIRHEUMATIC AGENT; CYCLOSPORIN A; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MITOGENIC AGENT; OVALBUMIN; RAPAMYCIN; TACROLIMUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNITY; CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SELECTIVITY; FEMALE; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPH NODE CELL; MACROPHAGE; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; SHEEP ERYTHROCYTE; SPLEEN CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODY FORMATION; ANTIRHEUMATIC AGENTS; CELLS, CULTURED; FEMALE; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; OVALBUMIN; RATS; RATS, INBRED LEW; SPIRO COMPOUNDS; SPLEEN;

EID: 0030855375     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(97)00003-9     Document Type: Article

References (28)

1. Albrightson-Winslow CR, Brickson B, King A, Olivera D, Short B, Saunders C, Badger AM. Beneficial effects of long-term treatment with SK&F 105685 in murine lupus nephritis. J Pharm Exp Ther 1990; 255: 382-387.
2. Albrightson CR, Bugelski PJ, Berkhout TA, Jackson B, Kerns WD, Organ AJ, Badger AM. Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes. J Pharm Exp Ther 1995; 689-698.
3. Badger AM. Discovery and development of the immunomodulatory azaspiranes. In: VJ Merluzzi and J Adams Eds. The Search for Anti-Inflammatory Drugs: Case Histories from concept to clinic, Birkhauser, 1995; 275-301.
4. Badger AM, Kupiec-Weglinski JW. Azaspiranes with therapeutic activity in animal models of autoimmune disease and organ transplantation. In: New Immunosuppressive Modalities in Organ Transplantation, 1994; 93-105.
5. Badger AM, Wright CS. SK&F 106615. Drugs of the Future 1995; 20: 893-896.
6. Badger AM, DiMartino MJ, Swift BA, Mirabelli CK. Immunomodulatory activity and non-specific suppressor cell generation by spirogermanium in murine and rat models of cell-mediated immunity. Immunopharmacology 1988; 16: 33-43.
7. Badger AM, DiMartino MJ, Talmadge JE, Picker DH, Schwartz DA, Dorman JW, Mirabelli CK, Hanna N. Inhibition of animal models of autoimmune disease and the induction of non-specific suppressor cells by SK&F 105685 and related azaspiranes. Int J Immunopharmacol 1989; 11: 839-846.
8. Badger AM, King AG, Talmadge JE, Schwartz DA, Picker DH, Mirabelli CK, Hanna N. Induction of non-specific suppressor cells in normal Lewis rats by a novel azaspirane SK&F 105685. J Autoimmun 1990; 3: 485-500.
9. Badger AM, Swift BA, Bugelski PJ. Suppressor cell (SC) activity induced by the azaspiranes may reside in a non-adherent or semi-adherent tissue macrophage population. J Immunol 1993; 150: 75A.
10. Bradbeer JN, Kapadia RD, Sarkar SK, Zhao H, Stroup GB, Swift BA, Rieman DJ, Badger AM. Disease-modifying activity of SK&F 106615 in rat adjuvant-induced arthritis. Arthritis Rheum 1996; 39: 504-514.
11. Bugelski P, Ruggieri E, Polsky R, Cunningham L, Handler J, Eustis S, Kapadia R, Sarkar S, Schnell M, Badger A, Herzyk D. Therapeutic effect of SK&F 106615 on pristane-induced arthritis in mice. Arthritis Rheum 1996.
12. Hancock WW, Schmidbauer G, Badger AM, Kupiec-Weglinski JW. SK&F 105685 suppresses allogeneically induced mononuclear and endothelial cell activation and cytokine production and prolongs rat cardiac allograft survival. Transplant Proc 1992; 24: 231-232.
13. Hein L, Lullmann-Rauch R, Mohr K. Human accumulation potential of xenobiotics: Potential of catamphiphilic drugs to promote their accumulation via inducing lipidosis or mucopolysaccharidosis. Xenobiotica 1990; 20: 1259-1267.
14. Herzyk DJ, Ruggieri EV, Badger AM, Bugelski PJ. Modulation of murine host defense against Candida albicans infection by the azaspirane, SK&F 106615. 9th Int Congr Immunology July 23-29, 1995; Abstr.: 858.
15. Herzyk DJ, Ruggieri EV, Cunningham L, Polsky R, Herold C, Badger AM, Kerns WD, Bugelski PJ. Host defense against Candida albicans: An effector mechanism based approach to immunotoxicity testing (part II). Toxicol Pathol, in press.
16. High WB, Bugelski PJ, Nichols ME, Swift BA, Solleveld HA, Badger AM. Effects of a novel azaspirane (SK&F 105685) on arthritic lesions in the adjuvant Lewis rat: Attenuation of the inflammatory process and preservation of skeletal integrity. J Rheumatol 1994; 21: 476-483.
17. Jerne NK, Nordin AA, Henry C. The agar plaque technique for recognizing antibody-producing cells. In: B Amos Ed. Cell Bound Antibodies, Wistar Institute, Philadelphia, PA, 1963; 109.
18. Kaplan JM, Badger AM, Ruggieri EV, Olivera DL, Newman-Tarr T, Bugelski PJ. Inhibition of lymphoproliferative responses by SK&F 105685, a novel anti-arthritic agent. J Clin Lab Immunol 1991; 36: 49-58.
19. Kaplan JM, Badger AM, Ruggieri EV, Swift BA, Bugelski PJ. Effects of SK&F 105685, a novel anti-arthritic agent, on immune function in the dog. Int J Immunopharmacol 1993; 15: 113-123.
20. King AG, Badger AM. Administration of an immunomodulatory azaspirane, SK&F 105685, or human recombinant interleukin-1 stimulates myelopoiesis and enhances survival from lethal irradiation in C57B1/6 mice. Exp Hematol 1991; 19: 624-628.
21. King AG, Olivera D, Talmadge JE, Badger AM. Induction of non-specific suppressor cells and myeloregulatory effects of an immunomodulatory azaspirane, SK&F 105685. Int J Immunopharmacol 1991; 13: 91-100.
22. McNulty MJ, Reasor MJ. Enhanced phagocytic and bactericidal activities of phospholipidotic rat alveolar macrophages. J Reticuloendothelial Soc 1981; 30: 539-549.
23. Olivera DL, Kaplan JM, Newman-Tarr T, Ruggieri EV, Badger AM. Divergent effects of rapamycin on mouse and rat cells following mitogenic stimulation. Clin Immunol Immunopathol 1993; 68: 357-362.
24. Rabinovitch A, Suarez WL, Qin H-Y, Power RF, Badger AM. Prevention of diabetes and induction of non-specific suppressor cell activity in the BB rat by an immunomodulatory azaspirane, SK&F 106610. J Autoimmun 1993; 1: 39-49.
25. Reasor MJ. A review of the biology and toxicologic implications of the induction of lysosomal lamellar bodies by drugs. Toxicol Appl Pharmacol 1989; 97: 47-56.
26. Schmidbauer G, Hancock WW, Badger AM, Kupiec-Weglinski JW. Induction of nonspecific X-irradiation-resistant suppressor cell activity in vivo and prolongation of vascularized allograft survival by SK&F 105685, a novel immunomodulatory azaspirane. Transplantation 1993; 55: 1236-1243.
27. Thiem PA, Kaplan JM, Bugelski PJ, Ruggieri EV, Badger AM. Induction of suppressor cell activity in vivo and suppression of lymphoproliferative responses in vitro by SK&F 105685 in the dog. Immunopharmacology 1992; 23: 67-74.
28. Waites CR, Bugelski PJ, Badger AM. Biochemical and functional analysis of rat bronchoalveolar macrophages containing chemically induced phospholipid inclusions. Toxicol Appl Pharmacol 1995; 130: 316-321.